In short
This article discusses the ongoing clinical trials of Satoreotide Trizoxetan Gallium (Ga68), also known as 68Ga-SATO, in pediatric patients with neuroblastoma. The study aims to assess the safety and effectiveness of this new imaging agent compared to current diagnostic methods. We'll explore the trial's objectives, eligibility criteria, and potential benefits for children with this rare cancer.
At a glance
- Drug Name
- Satoreotide Trizoxetan Gallium (Ga68) / 68Ga-SATO
- Trial Category
- Exploratory, safety, non-randomized, open-label, comparative study
- Main Objective
- Assess short-term safety and tolerability of 68Ga-SATO in pediatric neuroblastoma patients
- Secondary Objectives
- Compare 68Ga-SATO PET/CT to M123IBG scintigraphy and whole-body MRI; Calculate radiation absorbed dose; Evaluate procedure time
- Eligibility
- Pediatric patients with suspected or known neuroblastoma referred for M123IBG imaging
- Administration
- Intravenous injection
- Primary Endpoint
- Short-term safety and tolerability assessment using CTCAE v5.0
- Therapeutic Areas
- Diagnostic Techniques; Neoplasms
What is SATOREOTIDE TRIZOXETAN GALLIUM (GA68)?
SATOREOTIDE TRIZOXETAN GALLIUM (GA68), also known as 68Ga-SATO, is a diagnostic drug being studied for use in children with neuroblastoma. Neuroblastoma is a type of cancer that often affects young children and typically starts in the early nerve cells of the body.
This drug is also known by other names, including:
- SATOREOTIDE TRIZOXETAN GALLIUM GA-68
- OPS-202 GA-68
- 68Ga-SSO120
Purpose of the Study
The main goal of the study is to check if 68Ga-SATO is safe and well-tolerated by children with neuroblastoma. Researchers want to see if it can be used as a new way to detect and monitor this type of cancer.
How Does It Work?
68Ga-SATO is given as an intravenous injection, which means it's put directly into a vein. Once in the body, it helps create detailed images of the inside of the body using a special type of scan called PET/CT (Positron Emission Tomography/Computed Tomography).
These images can show where neuroblastoma tumors are in the body. This information is crucial for doctors to diagnose the disease and plan the best treatment.
Potential Benefits
The study aims to compare 68Ga-SATO PET/CT imaging with current methods used to detect neuroblastoma. These include:
- M123IBG scintigraphy: A type of scan currently used to detect neuroblastoma
- Whole body MRI: Another imaging technique that can show detailed pictures of the body
If 68Ga-SATO proves to be effective, it could offer several advantages:
- More accurate detection of tumors
- Potentially faster imaging procedure
- Possibly lower radiation exposure for patients
Safety Considerations
The study is designed to carefully monitor the safety of 68Ga-SATO. Researchers will be looking for any side effects or reactions that might occur after the injection. They will use a standardized system called CTCAE v5.0 (Common Terminology Criteria for Adverse Events) to record and grade any side effects.
Who Can Participate?
The study is open to children who either:
- Are suspected to have neuroblastoma and are getting their first M123IBG scan
- Have known neuroblastoma and are getting a follow-up M123IBG scan
However, some children cannot participate if they have:
- Severe auto-immune diseases
- Used certain medications recently, such as long-acting somatostatin analogs or diuretics
- Are pregnant (for older participants)
What Does the Procedure Involve?
If a child participates in the study, here's what they can expect:
- They will receive an injection of 68Ga-SATO through a vein.
- They will then have a PET/CT scan, which takes detailed pictures of the inside of their body.
- For some patients, multiple scans might be taken over time to calculate how the drug moves through the body.
- The results will be compared with their regular M123IBG scan and MRI (if available).
The researchers will also keep track of how long the entire procedure takes, from preparation to finishing the scan.